ライフサイエンスコーパス: gp160

1 candidate HIV-1 vaccine, oligomeric gp160 (o-gp160).

2 s whole envelope glycoprotein of Mr 160,000 (gp160).

3 tional domains (GLUT4 and the aminopeptidase gp160).

4 t mimic the native membrane-bound Env spike (gp160).

5 with recombinant vaccinia virus encoding HIV gp160.

6 ectodomain of the SIV envelope glycoprotein, gp160.

7 tigenic representations of virion-associated gp160.

8 ty of positive selection sites is located in gp160.

9 of the HIV-1 envelope glycoprotein precursor gp160.

10 ing multiple HIV-1 proteins, and recombinant gp160.

11 11-320 of the HIV IIIB envelope glycoprotein gp160.

12 vaccine strain-based vector expressing HIV-1 gp160.

13 the C-terminal calmodulin-binding domain of gp160.

14 binding to the C-terminal binding domain of gp160.

15 ion of gp160e, the soluble ectodomain of SIV gp160.

16 ion-competent vaccinia virus expressing 89.6 gp160.

17 osal infection with a virus expressing HIV-1 gp160.

18 ombinant vaccinia virus expressing HIV-1IIIB gp160.

19 th recombinant vaccinia expressing wild type gp160.

20 enhanced interaction of calnexin with HIV-1 gp160.

21 means to enhance the MHC II presentation of gp160.

22 ted greater responses than did the wild type gp160.

23 was degraded more rapidly than the wild type gp160.

24 e redundancy of the immune response to HIV-1 gp160.

25 sion of the envelope precursor glycoprotein, gp160.

26 igen, replacing the HIV-1 sequences encoding gp160.

27 ore epitopes located in different regions of gp160.

28 p120 and a second arm to the gp41 subunit of gp160.

29 riable domain 3 loop and in other regions of gp160.

30 d are internalized into cells expressing HIV gp160.

31 mpared to a 56:1 ratio for full-length Con-S gp160.

32 The HIV-1 envelope spike [Env; trimeric (gp160)3 cleaved to (gp120/gp41)3] induces membrane fusio

33 The HIV-1 envelope spike [trimeric (gp160)3, cleaved to (gp120/gp41)3] is the mediator of vi

34 of the HIV-1 envelope spike [Env; trimeric (gp160)3, cleaved to (gp120/gp41)3] poses challenges for

35 gp140 trimers, the uncleaved ectodomains of (gp160)3, have nearly all of the antigenic properties exp

36 er, the soluble and uncleaved ectodomain of (gp160)3, retains many antigenic properties of the intact

37 gp140 trimers-the uncleaved ectodomains of (gp160)3-from a few selected viral isolates adopt a compa

38 CD4 molecules on T cells with gp160 and anti-gp160 Ab showed markedly decreased apoptosis in Tat101 c

39 single VLP protein boost displaying trimeric gp160 adjuvanted with nanoparticle-encapsulated Toll-lik

40 In this work, we studied the solubility of gp160 after detergent extraction.

41 the C-terminal calmodulin-binding domain of gp160 (alanine 835 to tryptophan, A835W) eliminates gp16

42 ive healthy donors with HIV envelope protein gp160 alone or performed CD4XL with gp160 and anti-gp160

43 UNC gp160 also underwent more drastic soluble CD4 (sCD4)-ind

44 Interestingly, gp160 and ABCA1 interacted with calnexin differently; al

45 oss-linking of CD4 molecules on T cells with gp160 and anti-gp160 Ab showed markedly decreased apopto

46 protein gp160 alone or performed CD4XL with gp160 and anti-gp160 antibody.

47 The synthesis of gp160 and cleavage of gp160 to gp120 were not significan

48 odies showed poor recognition of recombinant gp160 and failed to neutralize a panel of viral isolates

49 with synthetic peptides spanning the entire gp160 and Gag coding region recognized a total of three

50 Both gp160 and gp120 from replication-competent FLAG variants

51 infectious progeny virus, and produced both gp160 and gp120.

52 ng trimers from nonfunctional Env (uncleaved gp160 and gp41 stumps).

53 ycoproteins (Env), including uncleaved (UNC) gp160 and gp41 stumps.

54 5 and the gp41 disulfide loop in unprocessed gp160 and processed gp120/gp41.

55 ctodomain and transmembrane domains of HIV-1 gp160 and the cytoplasmic domain of RV G.

56 nd scFv-TGN bound HIV gp160, and the scFv-ER-gp160 and the scFv-TGN-gp160 complexes were stable withi

57 tion of mature Env gp120 after cleavage from gp160 and trafficked out of the TGN.

58 and pSRHS delta 147, which express wild-type gp160 and truncated gp160, respectively, in the absence

59 the gp160 envelope or with a combination of gp160 and VSV-G envelopes did not influence the magnitud

60 n of their T-cell proliferation responses to gp160 and/or p24.

61 es, including the HIV envelope glycoprotein (gp160) and Vpr.

62 oximately 33% had proliferative responses to gp160, and approximately 42% showed p24 gag responses.

63 ytovirin binds to viral coat proteins gp120, gp160, and gp41 but not to cellular receptor CD4 or othe

64 viruses, expressing SHIV89.6 Gag-Pol or Env gp160, and inactivated SHIV89.6 virus.

65 The scFv-ER and scFv-TGN bound HIV gp160, and the scFv-ER-gp160 and the scFv-TGN-gp160 comp

66 seroconversion pattern, with initially only gp160 antibodies detected in the western blot.

67 hose immune sera with the highest oligomeric gp160 antibody binding titers had neutralizing activity

68 alone or performed CD4XL with gp160 and anti-gp160 antibody.

69 120-reactive MAbs recognized the primary UNC gp160 antigen of VLPs.

70 ry, vaccination with vCP1452 and recombinant gp160 appears safe and immunogenic in newly HIV-1-infect

71 c T-lymphocyte (CTL) responses against HIV-1 gp160 are induced by recombinant RVs.

72 GP38, GP85, and GP160 are likely soluble proteins based on the lack of p

73 Using a tumor expressing HIV gp160 as a model viral tumor Ag, we found a growth-regre

74 mster ovary (CHO)-K1 strain RPE.40 processed gp160 as efficiently as wild-type CHO-K1 cells in vivo.

75 ndoplasmic reticulum-localized glycoprotein (gp160) as well as a Golgi-specific form (gp170) which wa

76 It was expressed as gp160, as secreted gp140, and as gp160deltaCT with the c

77 d to calnexin but that only a portion of the gp160 associated with calnexin was also bound to calreti

78 The data suggested that most of the gp160 associated with calreticulin was also bound to cal

79 On the basis of reactivities with gp160 at different times after pulse-labeling, the MAbs

80 f calnexin to stimulate its interaction with gp160 at the expense of ABCA1.

81 We previously showed that envelope (gp160)-based vaccines, used in a live recombinant virus

82 We found that the same gp160-based vaccines were highly effective against intra

83 d in cytotoxic T lymphocyte activity against gp160-bearing targets and in lymphocyte proliferative ac

84 teracted with calnexin differently; although gp160 binding to calnexin was dependent on glycosylation

85 ng all or parts of gp41, including uncleaved gp160, binds spontaneously to free virions.

86 monoclonal antibodies directed against HIV-1 gp160 blocked the infectivity of both G-deficient viruse

87 without HIV envelope glycoprotein (gp120 or gp160) boosts accounted for all positive Western blot re

88 eficiency virus (HIV) envelope glycoprotein, gp160 bound transiently to calreticulin with a peak at 1

89 Increasing expression of wild type gp160, but not gp160A835W, correlates with increased cal

90 Furthermore, immunization with rLaSota/gp160 by any route or combination of routes induced a Th

91 ells display enhanced virion attachment in a gp160/CD4-dependent manner, which results in increased H

92 gnal-peptide cleavage occurs only late after gp160 chain termination and is dependent on folding of t

93 A subset of these gp160 clones are suitable for use as reference reagents

94 Individual gp160 clones were screened for infectivity as Env-pseudo

95 p160, and the scFv-ER-gp160 and the scFv-TGN-gp160 complexes were stable within HIV-infected transfec

96 es expressing only the N-terminal portion of gp160, containing P18 but not HP53.

97 c domain of the HIV-1 envelope glycoprotein (gp160) contains two palmitoylated cysteine residues.

98 The HIV-1 envelope glycoprotein, gp160, contains two C-terminal calmodulin-binding domain

99 As the HIV-1 envelope glycoprotein, gp160, contains two known calmodulin-binding domains, we

100 plasmic domain of the HIV-1 envelope protein gp160 could enhance Fas-mediated apoptosis, the major fo

101 by HIV-1 envelope glycoprotein (Env) if the gp160 cytoplasmic domain (CD) of HIV-1 Env is replaced b

102 Three expression plasmids encoding HIV(Ba-L) gp160, cytoplasmic gp140, and secreted gp140 were tested

103 alanine 835 to tryptophan, A835W) eliminates gp160-dependent enhanced FAS-mediated apoptosis in trans

104 combinant envelope proteins (Env, gp120, and gp160) derived from a single laboratory strain of HIV, d

105 bind H-2D(d) complexed with an HIV envelope gp160-derived peptide, P18-I10.

106 Expression of gp160 did not increase the virulence of recombinant NDV

107 that coimmunizing rhesus macaques with HIV-1 gp160 DNA and gp140 trimeric protein selected from nativ

108 aptured onto nanoparticles, each following a gp160 DNA prime.

109 Mice vaccinated with the formulated gp160 DNA vaccine showed potent antiviral immunity again

110 mediated immunity showed that the formulated gp160 DNA vaccine was more effective for stimulating env

111 oimmunized four times with selected multiple gp160 DNAs and gp140-trimeric envelope proteins.

112 of 17 HIV-2 strains where the extracellular gp160 domain was substituted into the HIV-2(7312A) provi

113 s, parenteral immunization of rabbits with o-gp160 elicited broad neutralizing serum Ab responses aga

114 tective responses; (ii) while both gp130 and gp160 elicited similar levels of SIV-specific antibodies

115 Boosting with gp120, compared with gp160, elicited significantly more NAs and CD4-blocking

116 cular peptide Ag; another H-2D(d)-restricted gp160 encoded epitope from a different HIV strain is not

117 The data indicate that gp160-enhanced apoptosis is dependent upon calmodulin up

118 We demonstrate that postponed cleavage of gp160 enhances functional folding of the molecule.

119 between soluble gp140 and virion-associated gp160 Env proteins derived from SF162 may be the basis f

120 es emerging from the latent reservoir showed gp160 env sequences that were identical to at least one

121 nodeficiency virus type 1) uses its trimeric gp160 envelope (Env) protein consisting of non-covalentl

122 DV, designated rLaSota/gp160, expressing the gp160 envelope (Env) protein of HIV-1 from an added gene

123 depends on the proteolytic maturation of the gp160 envelope glycoprotein precursor.

124 ese alpha helices, the normally labile HIV-1 gp160 envelope glycoprotein was converted into a stable

125 oid cells by binding CD4 molecules via their gp160 envelope glycoproteins.

126 hes could result in a new delivery method of gp160 envelope HIV-1 vaccine which could combine the pot

127 In vivo, lentiVLP pseudotyping with the gp160 envelope or with a combination of gp160 and VSV-G

128 two nonhomologous peptides of the HIV-1 IIIB gp160 envelope protein, P18 (residues 315-329) and HP53

129 esignated p15m and p54m, were located in the gp160 envelope protein.

130 y use of a third-generation native HIV(IIIB) gp160 enzyme immunoassay (EIA), detection of HIV antibod

131 Abs that preferentially react with monomeric gp160 exhibited diminished binding after the pulse.

132 our data suggest that membrane-expressed UNC gp160 exists in a less "triggered" conformational state

133 erated a recombinant NDV, designated rLaSota/gp160, expressing the gp160 envelope (Env) protein of HI

134 we use an HIV peptide immunogen and an HIV-1 gp160-expressing recombinant vaccinia viral intrarectal

135 The pro-apoptotic effect of gp160 expression is blocked by two calmodulin antagonist

136 Variant gp120 sequences were subcloned into gp160 expression plasmids with identical cleavage motifs

137 Proper gp160 folding in the ER requires core glycosylation, dis

138 evaluated in vaccinia vectors expressing HIV gp160 for the establishment of an effective vaccine stra

139 sera from mice immunized intranasally with o-gp160 formulated with liposomes plus MPL, proteosomes, a

140 his study, nasal immunization of mice with o-gp160, formulated with liposomes containing monophosphor

141 to cross-kill target cells expressing HIV-1 gp160 from heterologous HIV-1 strains.

142 0 or sodium metaperiodate-treated oligomeric gp160 from HIV-1(451) bound much more readily to CXCR4 t

143 res approximately 25% sequence identity with gp160 from the human immunodeficiency virus, type I, ind

144 ng HIV type I (HIV-1) envelope glycoprotein (gp160) from both a laboratory-adapted (CXCR4-tropic) and

145 on with a plasmid that encodes the HIV-1 env gp160 gene induced a strong anti-gp160 response as well.

146 expression of epitope mRNA, but retained the gp160 gene, MHC, and processing apparatus.

147 g, sequencing, and characterizing functional gp160 genes from 18 acute and early heterosexually acqui

148 To facilitate this, full-length gp160 genes were cloned from acute and early subtype B i

149 erived by proteolytic cleavage of a trimeric gp160 glycoprotein precursor.

150 Although the product of the env gene, gp160/gp120, is known to play a role in cell death media

151 mmune responses toward conserved epitopes of gp160, has longer expression time due to increased resis

152 h a multicomponent vaccine (multimeric HIV-1 gp160, HIV-1 Tat, and SIV Gag-Pol particles).

153 Furthermore, anti-gp160 IgG and IgA in vaginal secretions and fecal extrac

154 thin the RV genome was used to express HIV-1 gp160 in addition to the other RV proteins.

155 Expression of gp160 in Jurkat T-cells results in increased sensitivity

156 ciency virus type I (HIV-I) envelope protein gp160 in mammalian cells.

157 ic antibodies, gp130 was not as effective as gp160 in protection, indicating a possible role for the

158 Although furin can process gp160 in vitro, this processing is probably not physiolo

159 -Pol and the other expressing HIV-1 89.6 Env gp160 in WT or mutant forms.

160 o viral coat glycoproteins (gp120, gp41, and gp160) in a glycosylation-dependent manner.

161 In contrast, we find that a mutant gp160, in which the two palmitoylated cysteine residues

162 in the formation of virus with low levels of gp160 incorporation as well as a decrease in viral infec

163 cific for recombinant vaccinia virus-encoded gp160, indicating its ability to bind endogenously gener

164 culation of mice with an RV expressing HIV-1 gp160 induced a solid and long-lasting memory CTL respon

165 ce with the recombinant RVs expressing HIV-1 gp160 induced a strong humoral response directed against

166 ice with recombinant vaccinia expressing HIV gp160 induced specific serum antibody and strong HIV-spe

167 three recombinant adenoviruses containing a gp160 insert from human immunodeficiency virus type 1 (H

168 160 peptides recognized, and stimulated anti-gp160 intestinal IgA compared with immunization with unc

169 s revealed that the maturation processing of gp160 into gp120 and gp41 was blocked in the scFv-ER tra

170 did influence the cleavage of the precursor gp160 into its mature form, gp120.

171 n immunodeficiency virus-1 envelope protein, gp160, into gp120 and gp41 has been attributed to the ac

172 ize to lipid rafts and strongly suggest that gp160 is associated with lipid rafts.

173 Correct endoproteolytic maturation of gp160 is essential for the infectivity of human immunode

174 We show that wild-type gp160 is mostly insoluble after ice-cold Triton X-100 ex

175 ry proteins, the HIV-1 envelope glycoprotein gp160 is targeted to the endoplasmic reticulum (ER) by i

176 The precursor, gp160, is cleaved post-translationally into gp120 and gp

177 The trimeric HIV/SIV envelope glycoprotein, gp160, is cleaved to noncovalently associated fragments,

178 human immunodeficiency virus type 1 (HIV-1), gp160, is synthesized as a protein precursor that when p

179 sis confirmed that the rates of synthesis of gp160/LAMP and wild type gp160 were comparable and that

180 oteins has led to the application of a HIV-1 gp160/LAMP chimeric gene as a novel means to enhance the

181 cinated with recombinant vaccinia expressing gp160/LAMP had greater gp160-specific lymphoproliferatio

182 nofluorescence microscopy confirmed that the gp160/LAMP protein had a cellular localization correspon

183 med with cloned human cell lines showed that gp160/LAMP stimulated greater responses than did the wil

184 However, the gp160/LAMP was degraded more rapidly than the wild type

185 gp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone.

186 Additional information regarding gp160 maturation and intracellular trafficking was obtai

187 that inhibitors of proteolytic processing of gp160 may be useful for combating human immunodeficiency

188 ombinant RV, a rhabdovirus, expressing HIV-1 gp160 may serve as an effective vector for an HIV-1 vacc

189 ), both SIV and human immunodeficiency virus gp160 mediate viral entry by membrane fusion.

190 d from recipients of a canarypox ALVAC/HIV-1 gp160 (MN) vaccine were found capable of lysing autologo

191 t by oligomer-dependent MAbs were present on gp160 molecules associated with the molecular chaperone

192 Additionally, monomeric gp120 and uncleaved gp160 molecules have been shown to be poor antigenic rep

193 ity of a candidate HIV-1 vaccine, oligomeric gp160 (o-gp160).

194 not detected because proteolytic cleavage of gp160 occurs in the trans-Golgi.

195 ybrid fusion protein, combining domains from gp160 of HIV-1 and VSV-G.

196 opment by incorporating the envelope protein gp160 of HIV-1 primary isolate strain 89.6 (MVA 89.6) an

197 inant vaccinia virus expressing heterologous gp160 of primary HIV-1 isolates in a murine challenge sy

198 ccine expressing all SHIV89.6 genes plus Env gp160 of SHIV89.6P.

199 An associated processing defect in gp160 of SIVsmPBj6.9 and chimeras expressing the D119G s

200 expansion in culture, the complete envelope (gp160) of each isolate was verified by sequencing.

201 , the envelope glycoprotein (Env) precursor, gp160, of human immunodeficiency virus type 1 is cleaved

202 The envelope glycoprotein, gp160, of simian immunodeficiency virus (SIV) shares app

203 canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprote

204 ein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in

205 ssed at high levels, either as a full-length gp160 or as a soluble gp140 truncated immediately N-term

206 ons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deleti

207 e developed that inducibly express wild type gp160 or gp160A835W.

208 have been repeatedly shown to bind to HIV-1 gp160 or gp41, but fail to block viral entry.

209 o were immunized with either recombinant (r) gp160 or placebo every 2 months for 5 years.

210 ly only if a significant amount of uncleaved gp160 or synthetic MPER peptide was present.

211 When either gp160- or gp140-expressing plasmids and recombinant gp12

212 IgA and IgG titers, increased the number of gp160 peptides recognized, and stimulated anti-gp160 int

213 human immunodeficiency virus type 1 (HIV-1) gp160 precursor glycoprotein into gp120 and gp41 subunit

214 PE.40 cells, which efficiently processed the gp160 precursor in vitro.

215 ytic activation; specifically, cleavage of a gp160 precursor into gp120 and gp41 subunits creates an

216 ike is dependent on protease cleavage of the gp160 precursor protein in the Golgi apparatus.

217 Biochemical studies showed that gp160 present in infected cells and in the virion formed

218 vance priming with vaccinia virus expressing gp160 prevented only the initial tumor growth but not th

219 fter immunization with an adenovirus-HIV-1MN gp160 priming-HIV-1SF2 gp120 boosting regimen.

220 bjects revealed multiple sequence changes in gp160, principally within the variable domain 1/variable

221 rane-bound furin, PC5B, and PC7 and inhibits gp160 processing and HIV infectivity.

222 r, one mutation (D457R) caused a decrease in gp160 processing by approximately 80%.

223 on of the mutant Env into virions and normal gp160 processing.

224 The gp160 protein expressed by rLaSota/gp160 virus was detec

225 rabbits with an affinity-purified oligomeric gp160 protein formulated with either Alhydrogel or monop

226 The HIV-1 gp160 protein was stably and functionally expressed, as

227 y intranasal immunization with an oligomeric gp160 protein.

228 s of N-glycans were detected in the GP85 and GP160 proteins, both of which contain the mucin domain.

229 addition to the baculovirus-derived p24 and gp160 proteins.

230 A 10-min tag occurred before gp160 reacted with conformational MAbs that inhibited CD

231 markably, there was a 1- to 2-h delay before gp160 reacted with stringent oligomer-specific MAbs.

232 tically diverse viral clades, CTL from ALVAC/gp160 recipients showed both a broad pattern of cytolysi

233 pitopes exposed on native forms of gp120 and gp160, recognized a restricted number of linear epitopes

234 onsisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp

235 which express wild-type gp160 and truncated gp160, respectively, in the absence of other viral prote

236 e HIV-1 env gp160 gene induced a strong anti-gp160 response as well.

237 cycle because of the defective processing of gp160, resulting in the absence of gp120 on progeny viru

238 Sequence analysis of gp160 revealed a growing number of mutations over time,

239 ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific

240 ies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp16

241 ncy virus (HIV) type 1 envelope glycoprotein gp160 (rgp160) in 608 HIV-infected, asymptomatic volunte

242 th recombinant vaccinia virus(es) expressing gp160(s) and boosting with gp120 protein(s) from (i) LAI

243 was determined and aligned with 99 subtype A gp160 sequences from the Los Alamos HIV database.

244 gp160 complexed to proteosomes improved anti-gp160 serum IgA and IgG titers, increased the number of

245 mbinant glycosylated HIV-1 gp120 (sgp120) or gp160 (sgp160).

246 encoding human immunodeficiency virus type 1 gp160 significantly increased humoral responses by sever

247 stribution of HLA class I alleles, and HIV-1 gp160-specific IgA responses suggest a biologic basis fo

248 ences were seen in humoral immune responses: gp160-specific IgA responses were detected in cervicovag

249 r proteosomes with emulsomes elicited strong gp160-specific IgG and IgA responses in serum as well as

250 HIV-1 gp160-specific IgG responses were detected in >99% of mu

251 as an adjuvant elicited higher levels of SIV gp160-specific immunoglobulin G (IgG) in sera and IgA in

252 t vaccinia expressing gp160/LAMP had greater gp160-specific lymphoproliferation responses and higher

253 We found that gp160 stability in the endoplasmic reticulum (ER) and it

254 secreting cells, but only following in vitro gp160 stimulation.

255 processing of human immunodeficiency virus-1 gp160 synthesized in human cells from an infectious huma

256 an soluble gp120 and that MAb binding to UNC gp160 tends to have greater conformational consequences.

257 with one V3 and one gp41 sequence change in gp160 that conferred both altered replicative fitness an

258 nd to consist of an early, monomeric form of gp160 that is glycosylated in the endoplasmic reticulum

259 are synthesized as a polyprotein precursor (gp160) that is cleaved by cellular proteases to the matu

260 g a known D(d)-restricted epitope from HIV-1 gp160, the development of effector and memory cells CD8

261 zation with a vaccinia virus vector encoding gp160, the mAb blocks the subsequent appearance of CD8(+

262 human immunodeficiency virus type 1 (HIV-1) gp160 to create a hybrid fusion protein, gp160G.

263 The synthesis of gp160 and cleavage of gp160 to gp120 were not significantly affected by MA mut

264 we used paired IgA and IgG mAbs against HIV gp160 to study intraepithelial cell neutralization and i

265 A greater propensity of UNC gp160 to undergo conformational changes was also suggest

266 to maintain the quaternary structure of the gp160 trimer, as well as conformational masking of epito

267 immunodominant determinant within the HIV-1 gp160 V3 loop by three different class I MHC molecules t

268 vity was observed between weeks 8 and 10 for gp160-vaccinated mice, and activity remained detectable

269 In contrast to ALVAC/gp160 vaccinees, recipients of the ALVAC/HIV-1 immunogen

270 for the enhanced efficacy of the recombinant gp160 vaccines against the uncloned virus challenge by t

271 protective immunity elicited by recombinant gp160 vaccines is restricted primarily to the homologous

272 mian immunodeficiency virus SIVmne envelope (gp160) vaccines protected macaques against an intravenou

273 mian immunodeficiency virus SIVmne envelope (gp160) vaccines protected macaques against intravenous c

274 ag, Pol, and gp120 (vCP250) or Gag, Pol, and gp160 (vCP1420) in a prime-boost protocol with their hom

275 vaccine arm had new or boosted responses to gp160, versus approximately 18% in the placebo arm.

276 Guinea pigs were administered rLaSota/gp160 via the intranasal (i.n.) or intramuscular (i.m.)

277 intracellular complexes between CD4 and the gp160 viral envelope precursor but instead required the

278 dy neutralization, including mutation of the gp160 viral surface spike, a glycan shield to block anti

279 The gp160 protein expressed by rLaSota/gp160 virus was detected on an infected cell surface and

280 entially reactive with natively folded gp120/gp160 was dependent on the tertiary structure of the HIV

281 CD4-immunoglobulin, whereas only unprocessed gp160 was detected in 293T cells transfected with replic

282 tle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alone or with monomeric BaL g

283 Recurrent vaccination with recombinant gp160 was proven to be persistently immunogenic, increas

284 nsulin-responsive aminopeptidase (IRAP/VP165/gp160) was identified originally in GLUT4-containing ves

285 standard clonal analysis of full-length env (gp160) was performed on plasma HIV-1 samples obtained at

286 define a dominant CTL epitope for HIV-1 89.6 gp160, we mapped the epitope to a sequence, IGPGRAFYAR (

287 tes of synthesis of gp160/LAMP and wild type gp160 were comparable and that both proteins were proces

288 arious domains of the dualtropic HIV-1(DH12) gp160 were introduced into the genetic background of an

289 infected with a vaccinia virus encoding HIV gp160 were killed, demonstrating recognition of naturall

290 sites between the gp120 and gp41 subunits of gp160 were mutated to prevent cleavage and shedding of g

291 Those clones expressing gp160 were then cotransfected with an HIV-1 luciferase r

292 ing kinetics of calnexin and calreticulin to gp160 were very similar.

293 ld-type Env) and UNC VLPs (bearing uncleaved gp160) were recognized by various Env-specific monoclona

294 E4, a furin homologue, allowed processing of gp160 when both were expressed in RPE.40 cells.

295 Approximately 85% of the neurons expressed gp160 which underwent native post-translational cleavage

296 identified two additional proteins, GP85 and GP160, which contain both mucin and GP38 domain regions,

297 by the trimeric viral envelope glycoprotein gp160, which is processed by a single proteolytic cleava

298 , stimulated the antibody response to native gp160 while it retained its ability to induce a CTL resp

299 ese studies indicate that interaction of HIV gp160 with CD4 molecules activates the ras pathway in T

300 Formulations of o-gp160 with MPL-AF, proteosomes, emulsomes, or proteosome